Onconova Therapeutics Inc.

241 articles about Onconova Therapeutics Inc.

• Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

  4/2/2024

  Onconova Therapeutics, Inc., and Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID and other infectious diseases, announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction.

• Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

  3/8/2024

  Onconova Therapeutics, Inc. today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further characterize the mechanism of rigosertib at the American Association for Cancer Research Annual Meeting.

• Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

  12/12/2023

  Onconova Therapeutics, Inc. today announced preclinical data, highlighting narazaciclib’s preclinical activity in Bruton’s kinase inhibitor (BTKi)-resistant mantle cell lymphoma (MCL).

• Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

  12/8/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”) today announced preclinical data highlighting narazaciclib’s multi-kinase profile, broad anti-tumor activity and increased anti-tumor immunity, compared to palbociclib and other CDK4/6 inhibitors, in a poster presented at the San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023.

• Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

  11/28/2023

  Onconova Therapeutics, Inc. today announced that Steven Fruchtman, M.D., President & CEO, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University.

• Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

  11/14/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress.

• Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

  11/7/2023

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023.

• Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

  11/2/2023

  Onconova Therapeutics, Inc. announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition, taking place in San Diego, California from December 9 to 12, 2023.

• Onconova Expands Leadership Team with Two Key Appointments

  10/24/2023

  Onconova Therapeutics, Inc. announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer, and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development.

• Promising Preclinical Narazaciclib Data Presented at MCL Meeting

  10/19/2023

  Onconova Therapeutics, Inc. announced that one of the Company’s scientific collaborators, Gaël Roué, Ph.D., from the Josep Carreras Leukaemia Research Institute, Spain, made a podium presentation during the European MCL Network Annual Meeting in Dublin, Ireland on October 7, 2023 regarding promising ongoing preclinical studies of narazaciclib, in combination with ibrutinib and other targeted therapies used in the treatment for mantle cell lymphoma.

• Encouraging Rigosertib Data Presented at EADV as Late BreakerReporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need

  10/12/2023

  Onconova Therapeutics, Inc. announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa, associated with advanced/metastatic squamous cell carcinoma, will be presented in the Late Breaking News session at the EADV in Berlin, Germany.

• Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

  9/28/2023

  Onconova Therapeutics, Inc. today announced that a late-breaking abstract reporting the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced/metastatic squamous cell carcinoma (SCC) will be presented in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2023 Congress taking place October 11-14 in Berlin, Germany.

• Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

  9/6/2023

  Onconova Therapeutics, Inc. today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

• Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results

  8/10/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported second quarter 2023 financial results and provided an update on recent pipeline progress.

• Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023

  8/3/2023

  Onconova Therapeutics, Inc. announced that the Company intends to release its second quarter 2023 financial results on Thursday, August 10, 2023.

• Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

  6/14/2023

  Onconova Therapeutics, Inc. presented preclinical data on narazaciclib at the 17th International Conference on Malignant Lymphoma, which is taking place in Lugano, Switzerland, through June 17, 2023.

• Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

  6/5/2023

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced the presentation of a Trials in Progress poster at the American Society of Clinical Oncology Annual Meeting, which is taking place June 2 – 6, 2023 in Chicago, Illinois and online.

• Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

  5/25/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 trial of oral rigosertib plus the PD-1 inhibitor pembrolizumab in patients with metastatic melanoma who have progressed on prior PD-1/L1 inhibitor therapy.

• Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

  5/15/2023

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced financial results for the three months ended March 31, 2023, and provided a business update.

• Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

  5/12/2023

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”) today announced that Steven M. Fruchtman, M.D., President & CEO of Onconova Therapeutics, will participate in a Ladenburg Thalmann virtual R&D showcase on Thursday, May 18, 2023, at 11:00 a.m. ET.